BioSpace News Archive

SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will present at two upcoming virtual investor conferences in September.

Gain Therapeutics, Inc., a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, announced topline data from the Company’s study, conducted at the University of Maryland School of Medicine.

Monte Rosa Therapeutics, Inc. today announced that Markus Warmuth, M.D., Chief Executive Officer, and Ajim Tamboli, CFA, Chief Financial Officer, are scheduled to participate in a virtual fireside chat at 2 p.m. ET on Wednesday, Sept. 15 at the Morgan Stanley 19th Annual Global Healthcare Conference.

MiMedx Group, Inc. today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective.

Affinia Therapeutics today announced the first two indications it will pursue with its next-generation gene therapies

Qualigen Therapeutics, Inc. announced today that CEO and Chairman Michael Poirier will present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021.

Immunitas Therapeutics (“Immunitas”), a single cell genomics-based therapeutics company, has appointed Seng-Lai “Thomas” Tan, Ph.D., as Chief Scientific Officer.

NRx Pharmaceuticals today announced that NRx’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021 .

Ceapro Inc. announced that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Outlook Therapeutics, Inc. announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat during the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13 – 15, 2021.